Calidi Biotherapeutics to Showcase Innovative Cancer Immunotherapy Pipeline in Investor Webinar

Calidi Biotherapeutics, a biotechnology company specializing in innovative cancer immunotherapy, will host a live investor webinar on April 24, 2025, to provide insights into its emerging cancer treatment platforms. Led by newly appointed Chief Medical Officer Dr. Guy Travis Clifton, the webinar will offer a comprehensive overview of the company's advanced stem cell-based delivery technologies targeting various cancer types.

The presentation will focus on three key therapeutic programs: CLD-201, CLD-400, and CLD-101. CLD-201, which has already received FDA clearance, is positioned for clinical trials targeting solid tumors. CLD-400 is being developed to address metastatic and lung cancer, while CLD-101 is designed to target high-grade gliomas, representing a diverse approach to oncological treatment.

Calidi's unique technological approach centers on leveraging allogeneic stem cells as delivery mechanisms for oncolytic viruses. This innovative strategy aims to enhance the efficacy of cancer treatments while potentially improving patient safety. By utilizing stem cells as protective carriers, the company seeks to amplify the therapeutic potential of oncolytic viruses across multiple cancer indications.

The webinar represents a significant opportunity for investors and medical professionals to gain insight into emerging cancer immunotherapy technologies. Calidi's off-the-shelf, universal cell-based delivery platforms could potentially revolutionize cancer treatment by offering more targeted and adaptable therapeutic approaches.

Following the presentation, a live question-and-answer session will provide attendees with direct engagement opportunities to explore the nuanced details of Calidi's cancer immunotherapy pipeline. This interactive component underscores the company's commitment to transparency and scientific communication in developing advanced medical treatments.